Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE39198 | VANDA PHARMS INC | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics |
Nov, 2016
(7 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9138432 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Sep, 2025
(1 year, 5 months from now) | |
US8586610 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Nov, 2027
(3 years from now) | |
US9157121 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(5 years from now) | |
US8652776 | VANDA PHARMS INC | Prediction of QT prolongation based on SNP genotype |
Aug, 2030
(6 years from now) | |
US8999638 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(6 years from now) | |
US9074255 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(6 years from now) | |
US9072742 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(6 years from now) | |
US9074256 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(6 years from now) | |
US9074254 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(7 years from now) |
Fanapt is owned by Vanda Pharms Inc.
Fanapt contains Iloperidone.
Fanapt has a total of 10 drug patents out of which 1 drug patent has expired.
Expired drug patents of Fanapt are:
Fanapt was authorised for market use on 06 May, 2009.
Fanapt is available in tablet;oral dosage forms.
Fanapt can be used as method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine, method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6, dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone, indicated for the acute treatment of adults with schizophrenia, dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone.
Drug patent challenges can be filed against Fanapt from 06 May, 2013.
The generics of Fanapt are possible to be released after 28 December, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-180) | May 26, 2019 |
New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine; Method of treating schizophrenia by administering ilo...
Dosage: TABLET;ORAL